Gilead Sciences Inc GILD
News
Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD
Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026
Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026
Big pharma stocks close near all-time highs as tech selloff pushes investors toward safer bets
Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
Gilead Sciences On Track for Record High Close — Data Talk
Vir Biotechnology Shares Jump on Gilead Cancer Collaboration
Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
ITOC Stock Drop - Robbins LLP Reminds Investors They May Be Eligible to Lead the Class Action Lawsuit Against iTonic Holdings Ltd.
Assembly Biosciences Exercises U.S. Profit-Share Option for Herpes Program With Gilead
Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines
FDA Approves Gilead Sciences' Bixlenvo for Certain Adults With HIV
U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences
Lakefront Biotherapeutics Autoimmune Disorder Pemphigus Treatment Gets FDA Orphan Drug Designation
European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
Did You Lose Money Investing in iTonic Holdings Ltd.? Robbins LLP Urges Investors With Significant Losses to Contact the Firm for Information About Their Rights Against ITOC
Your prescription drugs shouldn't cost more than your mortgage. Inside the broken math that got us here.
CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results


